Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms REV 300, REV-300 |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Discovery | US | Revitope Oncology, Inc.Startup | 07 Sep 2022 |
Solid tumor | Discovery | US | 07 Sep 2022 |